Drug manufacturer Pfizer has announced plans that will see it expand into the generics market in Indonesia.
The clinical research firm will bolster its factory capacity in the Asia Pacific region and is set on investing $3 million (£1.9 million).
The expansion programme will result in Pfizer Indonesia doubling its manufacturing potential.
Its subsidiary on the ground, Pfizer Indonesia, is currently in talks with the National Drug and Food Monitoring Agency and hopes to have everything finalised before the end of the year.
Speaking to the Jakarta Post, Indonesia director at Pfizer Widyaretna Buenastuti said: "We offer an alternative for doctors when distributing medicine to patients, with no difference in quality between generic and our research-based drugs."
Pfizer may also be vying to offload its animal health business as it consolidates its offering.
Pfizer chief executive officer Ian Read said divesting the business, which generated revenues of $4.18 billion last year, was discussed at the firm's annual investor meeting.